Cushing's Syndrome Clinical Trial
OBJECTIVES:
I. Determine whether Cushing's syndrome and stress-induced pseudo-Cushing's syndrome can be
differentiated by evaluating endogenous corticotropin-releasing hormone activity.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
PROTOCOL ENTRY CRITERIA: Suspected adrenocorticotropin hormone (ACTH)-dependent Cushing's syndrome No pregnant women Effective contraception required of fertile women |
Primary Purpose: Screening
Country | Name | City | State |
---|---|---|---|
United States | Oregon Health Sciences University | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
National Center for Research Resources (NCRR) | Oregon Health and Science University |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02468193 -
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
|
Phase 2 | |
Recruiting |
NCT00457587 -
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
|
||
Completed |
NCT00006278 -
Study of Cushing's Syndrome Not Related to ACTH Production
|
N/A | |
Completed |
NCT00361777 -
Diagnostic Performance of Screening Tests for Cushing s Syndrome
|
||
Completed |
NCT03606408 -
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
|
Phase 2 | |
Completed |
NCT02663609 -
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
|
||
Recruiting |
NCT01504555 -
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
|
Phase 3 | |
Completed |
NCT02922257 -
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
|
||
Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
Terminated |
NCT00422201 -
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
|
Phase 2 | |
Completed |
NCT00001180 -
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
|
N/A | |
Completed |
NCT02804750 -
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
|
Phase 2 | |
Completed |
NCT00936741 -
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
|
Phase 3 | |
Recruiting |
NCT00004334 -
Study of Depression, Peptides, and Steroids in Cushing's Syndrome
|
N/A | |
Completed |
NCT03817840 -
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
|
||
Completed |
NCT01959711 -
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy
|
Phase 4 | |
Completed |
NCT05633953 -
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
|
||
Completed |
NCT02889224 -
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
|
N/A | |
Terminated |
NCT00796783 -
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
|
N/A | |
Recruiting |
NCT02019706 -
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
|
Phase 2 |